Arboretum Ventures

Arboretum Ventures LLC is a Michigan-based venture capital firm founded in 2002, specializing in seed-stage, early-stage, mid-stage investments, and growth capital in the healthcare sector. With a focus on services, medical devices, diagnostics, healthcare information technology, therapeutics, technology-based healthcare services, and life science tools, the firm invests throughout the United States, particularly in the Midwest and Michigan. Arboretum Ventures seeks to invest in companies with equity investments ranging from $5 million to $15 million. Headquartered in Ann Arbor, Michigan, the firm aims to support early-stage healthcare companies in the United States.

Amanda Elder

Vice President of Finance

Jan Garfinkle

Founder and Managing Partner

Sarah Jameson

Senior Associate

Dan Kidle

Managing Partner

Marcy Marshall

CFO

Paul McCreadie

Partner and COO

Suraj Mudichintala

Associate

Timothy B. Petersen

Founder and Managing Partner

Thomas Shehab

Managing Partner

Jon J. Snyder

Venture Partner

Nicole Walker

Managing Director

114 past transactions

Akadeum Life Sciences

Series B in 2021
Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other related areas. Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States.

Koya Medical

Series B in 2022
Koya Medical, Inc. develops technology device to treat cancer related chronic lymphedema and venous diseases. The company was founded in 2018 and is based in Oakland, California.

ArborMetrix

Series B in 2016
ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcare analytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals. It was founded in 2011 and headquartered in Ann Arbor, Michigan.

Flosonics

Venture Round in 2021
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.

Strata Oncology

Private Placement in 2018
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Intellicyt

Venture Round in 2013
IntelliCyt Corporation develops cell- and bead-based screening solutions using high throughput flow technology for use in drug discovery, antibody discovery, and immunology. It provides iQue Screener platform, an integrated instrument, software, and reagent system that enables high-content multiplexed analysis of cell- and bead-based samples in liquid suspension; ForeCyt software, an intuitive workflow-based environment for data visualization, instrument control, and data analysis; and MultiCyt screening kits–cell and bead-based reagents for use on iQue Screeners. The company also offers installation, training, technical support, and repair services. Its products are used in laboratories at pharmaceutical companies, biotechnology companies, and medical centers worldwide. IntelliCyt Corporation was formerly known as Sage Sciences, Inc. The company was founded in 2006 and is based in Albuquerque, New Mexico. As of June 28, 2016, IntelliCyt Corporation operates as a subsidiary of Sartorius AG.

SonarMD

Private Placement in 2018
SonarMD, LLC develops subspecialty practice platform for medical purpose. The company is based in Elgin, Illinois.

NeuMoDx Molecular

Series B in 2014
NeuMoDx Molecular, Inc. operates as a molecular diagnostics company. The company develops solutions for molecular diagnostic (MDx) testing in hospital and clinical reference laboratories. NeuMoDx Molecular, Inc. was formerly known as Molecular Systems Corporation and changed its name to NeuMoDx Molecular, Inc. in April 2013. The company was incorporated in 2012 and is based in Ann Arbor, Michigan. As of September 17, 2020, NeuMoDx Molecular, Inc. operates as a subsidiary of QIAGEN N.V.

My Health Direct

Venture Round in 2014
My Health Direct, Inc. develops a digital care coordination solution. The company offers MyHealthDirect, a referral management and online appointment-scheduling platform helps in actionable analytics, decision support, workflow management, and rapid implementation for organizations. It serves health systems, health plans, physician practices, hospitals, ACO and CIN, and community health. The company was founded in 2006 and is based in Nashville, Tennessee. As of August 8, 2019, My Health Direct, Inc. operates as a subsidiary of Experian Health, Inc.

Ebb Therapeutics

Series B in 2017
Ebb Therapeutics, Inc. develops regional cerebral thermal therapy (RCTT) device for use in insomnia and sleep disorders. It offers Ebb Insomnia Therapy, a drug-free insomnia therapy. Ebb Therapeutics, Inc. was formerly known as Cereve, Inc. Ebb Therapeutics, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

Strata Oncology

Series A in 2016
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Allay Therapeutics

Series C in 2021
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

BAROnova

Series A in 2006
BAROnova, Inc., a clinical-stage medical-device company, engages in developing non-surgical non-pharmacologic devices to induce weight loss. It develops TransPyloric Shuttle, a device that is inserted into the stomach through the mouth using a simple endoscopic procedure, as well as causes a patient’s stomach to fill up faster, stay full longer, and delay gastric emptying. BAROnova, Inc. was formerly known as Polymorfix, Inc. BAROnova, Inc. was founded in 2006 and is based in San Jose, California.

Accuri Cytometers

Series A in 2005
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Strata Oncology

Series C in 2021
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

BAROnova

Series B in 2008
BAROnova, Inc., a clinical-stage medical-device company, engages in developing non-surgical non-pharmacologic devices to induce weight loss. It develops TransPyloric Shuttle, a device that is inserted into the stomach through the mouth using a simple endoscopic procedure, as well as causes a patient’s stomach to fill up faster, stay full longer, and delay gastric emptying. BAROnova, Inc. was formerly known as Polymorfix, Inc. BAROnova, Inc. was founded in 2006 and is based in San Jose, California.

Esperion

Venture Round in 2013
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Hicuity Health

Series A in 2006
Advanced ICU Care® is the nation’s leading provider of high acuity telehealth services, contracted to provide care to nearly 100 hospitals in 27 states on a 24 x 7 x 365 basis. Advanced ICU Care is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

RareCyte

Series G in 2021
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its innovative technology to the Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. RareCyte's ground-breaking AccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) from whole blood.

ArborMetrix

Series B in 2013
ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcare analytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals. It was founded in 2011 and headquartered in Ann Arbor, Michigan.

Cardiac Dimensions

Private Placement in 2018
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Fifth Eye

Private Placement in 2019
Fifth Eye Inc., a medical software company, develops a real time analytics system designed to analyze hemodynamic instability in patients. It offers early warning system that continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods. The company's tool provides first score in five minutes with no baseline needed, minute-to-minute continuous patient assessment, advance warning and real-time treatment feedback, and historical trends without the need for electronic health record inputs. The company was formerly known as Trove Analytics, Inc. and changed its name to Fifth Eye Inc. in June 2018. Fifth Eye Inc. was incorporated in 2017 and is based in Ann Arbor, Michigan.

CardioMEMS

Venture Round in 2010
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

Esperion

Series A in 2008
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Cervilenz

Series A in 2012
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

KFx Medical

Series B in 2007
KFx® Medical, develops and manufactures innovative soft tissue fixation implants for orthopedic sports medicine surgeons. Our partnerships with the world's leading orthopaedic surgeons motivates us to develop new technology and proven surgical implants, resulting in positive surgical outcomes for the patients.

Strata Oncology

Series B in 2018
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Pear Therapeutics

Series A in 2016
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

BAROnova

Series C in 2013
BAROnova, Inc., a clinical-stage medical-device company, engages in developing non-surgical non-pharmacologic devices to induce weight loss. It develops TransPyloric Shuttle, a device that is inserted into the stomach through the mouth using a simple endoscopic procedure, as well as causes a patient’s stomach to fill up faster, stay full longer, and delay gastric emptying. BAROnova, Inc. was formerly known as Polymorfix, Inc. BAROnova, Inc. was founded in 2006 and is based in San Jose, California.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Cardiac Dimensions

Series B in 2018
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

CardioMEMS

Series F in 2009
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

SonarMD

Series A in 2018
SonarMD, LLC develops subspecialty practice platform for medical purpose. The company is based in Elgin, Illinois.

KFx Medical

Series A in 2005
KFx® Medical, develops and manufactures innovative soft tissue fixation implants for orthopedic sports medicine surgeons. Our partnerships with the world's leading orthopaedic surgeons motivates us to develop new technology and proven surgical implants, resulting in positive surgical outcomes for the patients.

Hicuity Health

Series B in 2008
Advanced ICU Care® is the nation’s leading provider of high acuity telehealth services, contracted to provide care to nearly 100 hospitals in 27 states on a 24 x 7 x 365 basis. Advanced ICU Care is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

EQRx

Series A in 2020
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

CardioMEMS

Series B in 2003
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

Accuri Cytometers

Series E in 2010
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Sonitus Medical

Series D in 2012
Sonitus Medical Inc., is a privately held medical device company committed to providing innovative and clinically effective hearing solutions that Otologists, ENTs, and Audiologists can use to help their patients rejoin the conversation of life. As an emerging leader in bone conduction hearing devices, Sonitus Medical currently markets the SoundBite Hearing System, the world's first non-invasive and removable hearing solution that imperceptibly transmits sound via teeth. Relying on the principle of bone conduction, this nearly invisible ITM (in-the-mouth) hearing system is a simple and non-surgical solution that is currently FDA cleared as a prosthetic device for the treatment of single sided deafness and conductive hearing loss. Intended future applications for this platform technology include indications for hearing disorders such as mixed hearing loss and tinnitus, as well as consumer and covert communications. Founded in June 2006, Sonitus Medical is headquartered in San Mateo, California.

Inogen

Series D in 2007
Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Health Scholars

Series B in 2020
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

Pear Therapeutics

Series B in 2018
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

BioIQ

Private Placement in 2018
BioIQ, Inc., a healthcare engagement and quality care company, develops health measurement software solutions to individuals. The company offers humanize analytics, analytics and omnichannel communications, and care navigation ecosystem for health plans, employers, and government. It serves national laboratories, diagnostics companies, digital health solutions, etc. The company was founded in 2005 and is based in Atlanta, Georgia.

Uptake Medical

Series B in 2010
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Cervilenz

Series E in 2012
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

Uptake Medical

Series C in 2012
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Accuri Cytometers

Series B in 2007
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

AtaCor Medical

Series C in 2024
AtaCor Medical, Inc. develops pacemaker system that keeps the heart and veins free from pacing leads and hardware. It offers AtaCor EV Temporary Pacing System, an implantable temporary pacing system that uses a parasternal approach for implantable, extravascular temporary pacing. The company’s AtaCor EV Temporary Pacing System advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium to restore cardiac rhythm for patients. AtaCor Medical, Inc. was incorporated in 2014 and is based in San Clemente, California.

ViaLase

Series C in 2024
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

Virtual Incision

Series C in 2023
Virtual Incision is the pioneer of in vivo mini-robot surgery, enabling minimally-invasive colon resection and other abdominal procedures. Colorectal cancer is the second-deadliest form of the disease, and along with conditions like Diverticulitis and Crohn’s, treatment often requires a colectomy, almost 400,000 of which are performed each year in the U.S. alone. Two-thirds of these procedures are still performed open, requiring a long, gruesome incision. VIC’s simpler/easier/cheaper approach is to insert a mini-robot into the insufflated abdomen via a small umbilical incision, after which the highly-dextrous robot arms are freely manipulated at the nearby surgeon console. VIC enables MIS colectomy using well-known laparoscopic tools, onboard vision, and leading multi-quadrant capabilities. After 70+ pig labs and with 60+ patents/applications, VIC is seeking a $15M Series B financing to achieve First-in-Man and prepare for CE Mark and FDA 510(k) submissions.

Convergent Dental

Venture Round in 2023
Convergent Dental is a privately owned dental equipment and technology company and developer of Sole, the world’s first computer-aided, CO2 laser system to ever be cleared by the FDA for both hard and soft tissue indications. Solea cuts significantly quieter, finer, and faster than any other laser-based system in dentistry. Solea’s speed and precision are a result of patented technologies and computer system controls that are unique to Convergent Dental, Inc. Convergent Dental unique system, with patented technologies and controls, nearly eliminates the need for the drill. The company was founded in 2011 and is based in Needham, Massachusetts, United States.

Cardiac Dimensions

Series D in 2023
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Navv Systems

Series A in 2022
Navv Systems, is a software solutions and platform company that uses Indoor Positioning technology (IPS) to provide traffic control for hospitals, warehouses, manufacturing, and other large, complex organizations.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

Francis Medical

Private Placement in 2018
Francis Medical, Inc. develops vapor ablation therapy devices that treat a variety of urological cancers, including Prostate Cancer (PCa), kidney, and bladder cancers. The company was founded in 2018 and is headquartered in Maple Grove, Minnesota.

Navv Systems

Seed Round in 2021
Navv Systems, is a software solutions and platform company that uses Indoor Positioning technology (IPS) to provide traffic control for hospitals, warehouses, manufacturing, and other large, complex organizations.

Francis Medical

Series B in 2021
Francis Medical, Inc. develops vapor ablation therapy devices that treat a variety of urological cancers, including Prostate Cancer (PCa), kidney, and bladder cancers. The company was founded in 2018 and is headquartered in Maple Grove, Minnesota.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Pear Therapeutics

Private Placement in 2020
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

Convergent Dental

Series C in 2021
Convergent Dental is a privately owned dental equipment and technology company and developer of Sole, the world’s first computer-aided, CO2 laser system to ever be cleared by the FDA for both hard and soft tissue indications. Solea cuts significantly quieter, finer, and faster than any other laser-based system in dentistry. Solea’s speed and precision are a result of patented technologies and computer system controls that are unique to Convergent Dental, Inc. Convergent Dental unique system, with patented technologies and controls, nearly eliminates the need for the drill. The company was founded in 2011 and is based in Needham, Massachusetts, United States.

Advance Medical

Series B in 2013
Advance Medical is one of the largest, physician-based telemedicine providers, offering employers and insurers the ability to provide top-quality, concierge-level medical advice and support to patients around the globe via offices in the U.S., Europe, Asia, and South America. Founded in 1999, Advance Medical has emerged as the global leader in expert medical opinions because of its programs executed exclusively by board-certified physicians – doctors who speak by phone or video consultation with every patient, no matter what the issue or concern and for as much time as necessary, to provide best-in-class medical expertise.

ViaLase

Series A in 2021
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

Enumera Molecular

Series A in 2022
Enumera Molecular is a life science tools company headquartered in Ann Arbor, MI, developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests. It helps in transforming the field of clinical molecular testing into a simpler, more actionable tool for physicians to benefit patient care.

HealthMedia

Venture Round in 2005
Founded in 1998, by Dr. Victor Strecher, HealthMedia® has developed a methodology and technology that effectively emulates a health coaching session, without the coach. Our one-of-a-kind programs possess the scalability of web content and deliver the efficacious outcomes a health coaching program receives.

Pear Therapeutics

Series C in 2019
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

HandyLab

Series D in 2008
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Accuri Cytometers

Series D in 2009
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

BioIQ

Venture Round in 2018
BioIQ, Inc., a healthcare engagement and quality care company, develops health measurement software solutions to individuals. The company offers humanize analytics, analytics and omnichannel communications, and care navigation ecosystem for health plans, employers, and government. It serves national laboratories, diagnostics companies, digital health solutions, etc. The company was founded in 2005 and is based in Atlanta, Georgia.

Cardiac Dimensions

Private Placement in 2020
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

nVision Medical

Series B in 2016
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

Swift Biosciences

Series D in 2017
Swift Biosciences, Inc. develops molecular biology reagents for research and diagnostic applications. Swift Biosciences, Inc. is based in Ann Arbor, Michigan.

EQRx

Private Placement in 2020
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

NeoGuide Systems

Series B in 2003
NeoGuide Systems Inc. develops robotic endoscopic technology for natural orifice transluminal endoscopic surgery. Its technology is used in colonoscopy application to provide access to abdominal and thoracic cavities. The company was founded in 2000 and is based in San Jose, California.

Adavium

Private Equity Round in 2013
Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that we commercialize on behalf of leading international companies. Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards. Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region. The company was founded in 2011 and is headquartered in Sao Paulo, Brazil.

Cervilenz

Venture Round in 2011
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

Fifth Eye

Series A in 2019
Fifth Eye Inc., a medical software company, develops a real time analytics system designed to analyze hemodynamic instability in patients. It offers early warning system that continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods. The company's tool provides first score in five minutes with no baseline needed, minute-to-minute continuous patient assessment, advance warning and real-time treatment feedback, and historical trends without the need for electronic health record inputs. The company was formerly known as Trove Analytics, Inc. and changed its name to Fifth Eye Inc. in June 2018. Fifth Eye Inc. was incorporated in 2017 and is based in Ann Arbor, Michigan.

Asterand

Series C in 2003
Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. From our offices in Detroit, MI and Royston, U.K., our employees focus on providing services and products to accelerate drug discovery research from target identification through compound evaluation and drug safety.

Uptake Medical

Series A in 2006
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

NxThera

Series B in 2011
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Accuri Cytometers

Series C in 2008
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Jumpcode Genomics

Funding Round in 2020
JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance. CRISPRclean is a proprietary technology that utilizes the CRISPR/CAS system to cut through the noise by removing unwanted nucleic acid molecules from sequencing libraries while preserving the representational integrity of the non-targeted sequences. Keith Brown founded the company in Carlsbad, California in 2016.

Tangent Medical Technologies

Venture Round in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Pear Therapeutics

Private Placement in 2018
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

Lucina Health

Seed Round in 2019
Lucina Health is a data-driven, enterprise SaaS company that delivers the leading women’s maternity analytics platform to innovative health plans, Medicaid providers and public entities. Lucina Health identifies women at-risk of preterm birth, usually within the first trimester, with personalized health improvement resources, making it easy for care managers to complete actions that optimize the health and well-being of women to improve birth outcomes and to create healthier communities over time.

Francis Medical

Series A in 2018
Francis Medical, Inc. develops vapor ablation therapy devices that treat a variety of urological cancers, including Prostate Cancer (PCa), kidney, and bladder cancers. The company was founded in 2018 and is headquartered in Maple Grove, Minnesota.

Wellfount

Series A in 2011
Wellfount Corp. offers pharmacy services to nursing facilities. The company offers utilization and compliance reviews, multi dose, compliance packaging used for cycle and routine meds, proprietary SOPs and clinical programs, daily deliveries, intravenous therapy (IV), total parenteral nutrition (TPN), customized invoicing, EHR application integration, and medical records. It also offers medications and consulting services. Wellfount Corp. was founded in 2006 and is based in Indianapolis, Indiana.

Koya Medical

Venture Round in 2020
Koya Medical, Inc. develops technology device to treat cancer related chronic lymphedema and venous diseases. The company was founded in 2018 and is based in Oakland, California.

My Health Direct

Series B in 2011
My Health Direct, Inc. develops a digital care coordination solution. The company offers MyHealthDirect, a referral management and online appointment-scheduling platform helps in actionable analytics, decision support, workflow management, and rapid implementation for organizations. It serves health systems, health plans, physician practices, hospitals, ACO and CIN, and community health. The company was founded in 2006 and is based in Nashville, Tennessee. As of August 8, 2019, My Health Direct, Inc. operates as a subsidiary of Experian Health, Inc.

Hicuity Health

Series D in 2011
Advanced ICU Care® is the nation’s leading provider of high acuity telehealth services, contracted to provide care to nearly 100 hospitals in 27 states on a 24 x 7 x 365 basis. Advanced ICU Care is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

Cardiac Dimensions

Series A in 2014
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

BioIQ

Private Placement in 2019
BioIQ, Inc., a healthcare engagement and quality care company, develops health measurement software solutions to individuals. The company offers humanize analytics, analytics and omnichannel communications, and care navigation ecosystem for health plans, employers, and government. It serves national laboratories, diagnostics companies, digital health solutions, etc. The company was founded in 2005 and is based in Atlanta, Georgia.

Mirabilis Medical

Series A in 2007
Mirabilis Medical, Inc. designs, develops, manufactures, distributes, installs, and services ultrasound devices for the non-invasive ablation of uterine fibroid tissue in the field of gynecology. Its device uses high resolution ultrasound imaging to localize treatment and a proprietary ultrasound technology to non-invasively treat tissue deep in the body. The company was founded in 2004 and is based in Bothell, Washington.

Health Scholars

Private Placement in 2019
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

Cervilenz

Series A in 2009
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

PathCentral

Series B in 2010
PathCentral, an Irvine, California-based provider of a fully integrated, web-based enterprise software platform designed specifically for community pathologists. Created by a team of pathologists and industry executives, PathCentral's solution integrates all aspects of a pathology practice's business, including ordering (accessioning), barcode-based laboratory workflow management and specimen tracking, transcription, test send-outs, professional consultations, diagnosis, reporting, billing and financial analysis.